Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824836 · ClinicalTrials.gov registry record · NA
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
A NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 1,046
- Enrollment target
- 2
- Study locations
NCT01824836 is a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,046 participants, above the 284-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (268% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01824836, a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,046 participants
- Enrollment target
- 2
- Study locations
Study Summary
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS). Women with stage I-III breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join.
Conditions Studied
Interventions
- DRUG anastrozole
Study Locations (2)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
New Jersey
- Veterans Adminstration New Jersey Health Care System - East Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2013-06-11 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824836
The ClinicalTrials.gov registry entry for NCT01824836 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,046 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 284-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (268% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which anastrozole is the first listed.
NCT01824836 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01824836 about?
NCT01824836 is a clinical study titled "A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)". E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS). Women with stage I-III breast cancer who are prescribed the aromatase inhibi...
What is the current status of trial NCT01824836?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,046 participants. The study started on 2013-06-11. Estimated completion is 2026-12.
What conditions does trial NCT01824836 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT01824836?
The interventions under investigation include: anastrozole (DRUG).
Who is sponsoring clinical trial NCT01824836?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01824836 being conducted?
This trial has 2 study locations across Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
ACTIVE NOT RECRUITING · NA
-
Researching the Effect of Exercise on Cancer
ACTIVE NOT RECRUITING · NA
-
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.